FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed are an antibody and its antigen-binding fragment capable of specific binding to PD-L1. Also an expression vector, a host cell and an immunoconjugate are considered. Also described is a method for detecting the presence or level of PD-L1 expression.
EFFECT: present invention can find further application in diagnosing and evaluating treatment of various cancers.
68 cl, 18 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
